| Original drug |
Bevacizumab (Avastin®) – monoclonal antibody targeting VEGF‑A, first‑line for several solid tumors and ocular neovascular diseases. |
| Patent landscape |
The core patents on bevacizumab expired in the EU (2018) and in the U.S. (2024). However, the U.S. drug remains off‑patent only in terms of “patent protection” – it is still marketed by only one manufacturer, and there is no U.S.‑registered biosimilar yet. |
| Regulatory approvals |
• EU – 5 biosimilars (e.g., Zirabev®, Bevacizumab‑Biosimilar® [BMS], Bevacizumab‑Biosimilar® [Sino‑Pharma], Bevacizumab‑Biosimilar® [CIS]) approved between 2018‑2022.
• U.S. – No FDA‑approved bevacizumab biosimilar as of Aug‑2026.
• Asia – Several approvals in India, China, and other markets (e.g., Zirabev®, BSA‑Biosimilar®). |
| Key players |
Mediheal (Zirabev®), Biogen (Bevima® – ocular), SinoPharma (Bevacizumab‑Biosimilar®), CIS Bio (Biosimilar), Sartorius (Bevacizumab‑Biosimilar®), UCB Pharma (Bevacizumab‑Biosimilar®). |
| Market size |
• Global: ≈ $5.5–6 billion in 2023 (mostly from ocular indications).
• EU: > $1.5 billion (with ~ 30% biosimilar uptake by 2025).
• U.S.: ≈ $4 billion (all Avastin®); biosimilar penetration expected to reach 15–20 % by 2027‑2028.
• Ophthalmic sub‑market: > $1 billion (neovascular AMD, diabetic retinopathy). |
| Pricing & Reimbursement |
• EU: Average wholesale price for Avastin® ~ $5,500–$7,000 per vial; biosimilar prices 15–25 % lower.
• U.S.: Wholesale price ≈ $6,300 per vial; biosimilar would target 20–30 % discount.
• Reimbursement: Many payors use a “step‑down” strategy—first‑line bevacizumab (biosimilar or reference) for ocular diseases, then switch to aflibercept or ranibizumab if needed. |
| Clinical data |
• Biosimilars demonstrate identical safety, efficacy, and PK/PD profiles in pivotal oncology and ocular trials.
• For ophthalmology, the FDA’s “broadly similar” criteria allow use of reference‑drug data (Avastin®) as a surrogate for ocular indications.
• Real‑world evidence (RWE) in EU shows no significant differences in visual‑acuity outcomes. |
| Barriers to adoption |
1. Interchangeability: FDA has not designated any bevacizumab biosimilar as interchangeable; prescribers must maintain the original drug. 2. Physician inertia: Many oncologists/ophthalmologists prefer the reference drug for “first‑line” therapy. 3. Reimbursement rules: Some insurers require “exclusive use” of the reference drug before allowing a biosimilar. 4. Supply chain complexity: Biosimilars often require cold‑chain logistics and specialized handling. |
| Competitive dynamics |
• Price war: The first EU biosimilar (Zirabev) captured ~ 30 % of the market within two years, forcing reference drug prices to drop 5–7 %.
• Bundled contracts: Ophthalmology payors bundle bevacizumab with other anti‑VEGF agents to maximize cost savings.
• Patent litigation: Several litigation cases in the U.S. over “biosimilar exclusivity” have delayed approvals. |
| Future outlook |
• U.S. market: Expected to reach 30 % biosimilar penetration by 2029 as the FDA issues more interchangeability designations and insurers adopt step‑down policies.
• Ocular indications: Continued growth driven by aging populations and new indications (e.g., retinal vein occlusion).
• Technological advances: Improved analytical methods (mass spectrometry, glycan profiling) may accelerate approval of next‑generation bevacizumab biosimilars with even lower cost.
• Emerging markets: Rapid uptake in Asia‑Pacific; India alone accounts for > 30 % of global biosimilar bevacizumab volume. |
| Key take‑aways |
1. Biosimilars are reshaping the bevacizumab landscape—in the EU they are already driving price reductions and increasing accessibility. 2. U.S. remains a laggard due to regulatory, reimbursement, and payer‑policy hurdles. 3. Ophthalmology is the fastest‑growing sub‑segment, where biosimilars can deliver the greatest cost savings. 4. Physicians and payors need clarity on interchangeability—once the FDA grants it, adoption will accelerate. |